Reduced Fc RI-Mediated Release of Asthma-Promoting Cytokines and Chemokines from Human Basophils during Omalizumab Therapy

Janet M. Oliver,Christy A. Tarleton,Laura Gilmartin,Tereassa Archibeque,Clifford Qualls,Lorena Diehl,Bridget S. Wilson,Mark Schuyler

Reduced Fc RI-Mediated Release of Asthma-Promoting Cytokines and Chemokines from Human Basophils during Omalizumab Therapy

2010

Janet M. Oliver
Christy A. Tarleton
Laura Gilmartin
Tereassa Archibeque
Clifford Qualls
Lorena Diehl
Bridget S. Wilson
Mark Schuyler

Background: Treating asthmatics with the humanized IgE-scavenging antibody, omalizumab (rhuMAb-E25, Xolair®), reduces airways inflammation and asthma symptoms. Previously, omalizuma

Keywords:

Immunology
Basophil
Omalizumab
Inflammation
Anti-asthmatic Agent
Chemokine
Immunoglobulin E
Asthma
Cytokine
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations